Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072460 | 1.00 | KMT2A (0.45) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL29467621 | 0.94 | TLR2 (0.44) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL23080632 | 0.91 | GLP1R (0.45) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL31235864 | 0.90 | MEN1 (0.42) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL29467729 | 0.89 | TLR2 (0.49) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL24588993 | 0.89 | KMT2A (0.49) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL23080633 | 0.88 | GLP1R (0.42) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL25544093 | 0.88 | GLP1R (0.42) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL28691663 | 0.88 | TLR2 (0.49) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL21055933 | 0.88 | LMNA (0.45) | TLR2TLR1BCHEACHESIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859493-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| EP-2292653-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2014-05-21 | — | — | EP | disclosed |
| EP-1846447-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-08-21 | — | — | EP | disclosed |
| US-20120208749-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-08-16 | — | — | US | disclosed |
| EP-2292653-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227796-A1 | Insulin Derivatives | IAPP, INSR, GCG | KMT2A 4184/4885MEN1 2119/4885ALDH1A1 4360/4885 |
| US-20120208749-A1 | Insulin derivatives | IAPP, INSR, GCG | KMT2A 4370/4885MEN1 1847/4885ALDH1A1 4330/4885 |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | KMT2A 4091/4885MEN1 2390/4885ALDH1A1 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.